Insulin therapy and cardiovascular complications
Authors:
Milan Kvapil
Authors place of work:
Interní klinika 2. LF UK a FN v Motole, Praha
Published in the journal:
Forum Diab 2017; 6(2): 61-66
Category:
Topic
Summary
Insulin has a proatherogenic effect, endogenous hyperinsulinemia is associated with a higher cardiovascular risk. The treatment by exogenous insulin may increase cardiovascular risk due to a higher risk of hypoglycemia. This can be efficiently eliminated by using new insulin analogues. According to the ORIGIN study, the therapy by exogenous insulin analogue does not in itself increase cardiovascular risk. However insulin as ultimum refugium for patients with type 2 diabetes mellitus is a signal of the primarily increased CV risk. Therefore it is important to make every effort to slow the progression of type 2 diabetes mellitus by all means, which can be, paradoxically, also supported by a timely and safe insulin therapy.
Key words:
atherosclerosis, diabetes mellitus, ischemic heart disease, insulin, insulin analogues, mortality, stroke
Received:
28.4.2017
Accepted:
9.5.2017
Zdroje
1. Lind M, Svensson AM, Kosiborod M et al. Glycemic Control and Excess Mortality in Type 1 Diabetes. N Engl J Med 2014; 371(21): 1972–1982. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1408214>.
2. Guzder RN, Gatling W, Mullee MA et al. Early mortality from the time of diagnosis of Type 2 diabetes: a 5-year prospective cohort study with a local age- and sex-matched comparison cohort. Diabet Med 2007; 24(10): 1164–1167.
3. Nathan DM. [DCCT/EDIC Research Group]. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care 2014; 37(1): 9–16. Dostupné z DOI: <http://dx.doi.org/10.2337/dc13–2112>.
4. Gerstein HC, Miller ME, Genuth S et al. [ACCORD Study Group]. Long-term effects of intensive glukose lowering on cardiovascular outcomes. N Engl J Med 2011; 364(9): 818–828. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1006524>.
5. [Diabetes Control and Complications Trial Research Group]. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 1995; 102(4): 647–661.
6. [UK Prospective Diabetes Study (UKPDS) Group]. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–853. Erratum in Lancet 1999; 354(9178): 602.
7. Collins R, Armitage J, Parish S et al. [Heart Protection Study Collaborative Group]. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361(9374): 2005–2016.
8. Weng J, Li Y, Xu W et al. Effect of intensive insulin therapy on beta cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371(9626): 1753–1760. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(08)60762-X>.
9. Retnakaran R, Zinman B. Short term intensified insulin treatment in type 2 diabetes: long term effects on beta cell function. Diabetes Obes Metab 2012; 14(Suppl 3):161–166. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1463–1326.2012.01658.x>.
10. ÚZIS ČR. Diabetologie, péče o diabetiky. Dostupné z WWW: <http://www.uzis.cz/category/tematicke-rady/zdravotnicka-statistika/diabetologie-pece-diabetiky> [26. 9. 2015].
11. Haffner SM, Lehto S, Rönnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339(4): 229–234.
12. Yudkin JS, Chaturvedi N. Developing risk stratification charts for diabetic and nondiabetic subjects. Diabet Med 1999;16(3): 219–227. Erratum in Diabet Med 1999; 16(11): 972–973.
13. [Česká diabetologická společnost (ČDS)]. Doporučený postup péče o diabetes mellitus 2. typu. Dostupné z WWW: <http://www.diab.cz/dokumenty/dm2_12.pdf>. [26. 9. 2015].
14. Kvapil M, Pavlík T, Titman O et al. Kvalita péče pacienty s diabetes mellitus v České republice: Analýza pro rok 2011. In: Kvapil M (ed). Diabetologie 2011. Triton: Praha 2011: 261 – 273. ISBN 978–80–7387–461–2.
15. Brož J, Honěk P, Dušek L et al. The mortality of patients with diabetes mellitus using oral antidiabetic drugs in the Czech Republic decreased over the decade of 2003–2013 and came closer to the population average. Vnitr Lek 2015; 61(11 Suppl 3): 3S14–3S20.
16. Zdravotnictví ČR: Stručný přehled mortalitních dat ČR z listu o prohlídce zemřelého 2004–2015 NZIS REPORT č. R/2 (09/2016). Dostupné z WWW: http://www.uzis.cz/publikace/zdravotnictvi-cr-strucny-prehled-mortalitnich-dat-cr-listu-prohlidce-zemreleho-2004–2015
17. Holleman F, Schmitt H, Rottiers R et al. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patiens treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 1997; 20(12): 1827–1832.
18. Heller S, Bode B, Kozlovski P et al. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus. J Diabetes 2013; 5(4): 482–491. Dostupné z DOI: <http://dx.doi.org/10.1111/1753–0407.12060>.
19. Fullerton B, Siebenhofer A, Jeitler K et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev 2016; (6): CD012161. Dostupné z DOI: <http://dx.doi.org/10.1002/14651858.CD012161>.
20. Janíčková Žďárská D, Kvapil M, Rušavý Z et al. Comparison of glucose variability assessed by a continuous glucose-monitoring system in patients with type 2 diabetes mellitus switched from NPH insulin to insulin glargine: the COBIN2 study. Wien Klin Wochenschr 2014; 126(7–8): 228–237. Dostupné z DOI: <http://dx.doi.org/10.1007/s00508–014–0508–6>.
21. Janíčková Žďárská D, Brož J, Křivská B et al. Basal insulin margine using a basal-bolus regimen in a common clinical practice: observational, non-interventional, multicenter, national project LINDA (Lantus in daily practice – safety and efficacy in basal bolus regimen). Vnitr Lek 2014; 60(9): 712–719.
22. Rhoads GG, Kosiborod M, Nesto RW et al. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. Am J Cardiol 2009; 104(7): 910–916. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2009.05.030>. Erratum in Am J Cardiol 2010; 106(4) :603.
23. Vehkavaara S, Yki-Järvinen H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2004; 24(2): 325–330.
24. Dandona P, Chaudhuri A, Ghanim H et al. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol 2007; 99(4A): 15B-26B.
25. Nathan DM, Cleary PA, Backlund JY et al. [Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group]. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25): 2643–2653.
26. Orchard TJ, Nathan DM, Zinman B et al. [Writing Group for the DCCT/EDIC Research Group]. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA 2015 ;313(1): 45–53. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2014.16107>.
27. Gerstein HC, Bosch J, Dagenais GR et al. [ORIGIN trial investigators]. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367(4): 319–328. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1203858>.
28. Rušavý Z, Lacigová S, Kvapil M. What has the largest study in the history of diabetology brought us? Vnitr Lek 2013; 59(3): 160–164.
29. Heller S, Mathieu C, Kapur R et al. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Diabet Med 2016; 33(4): 478–487. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.13002>.
30. Ritzel R, Roussel R, Bolli GB et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015; 17(9): 859–867. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12485>.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Forum Diabetologicum
2017 Číslo 2
Najčítanejšie v tomto čísle
- Overinsulinization – the frequent cause of unsatisfactory glycemic control: case reports
- Insulin in the therapeutic scheme for type 2 diabetes mellitus
- Insulin therapy during pregnancy
- Factors conducive to optimal control of type 1 diabetes mellitus in childhood and adolescence